297 related articles for article (PubMed ID: 22361010)
41. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
42. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
[TBL] [Abstract][Full Text] [Related]
43. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Cao R; Chen C; Wen J; Zhao W; Zhang C; Sun L; Yuan L; Wu C; Shan L; Xi M; Sun H
Bioorg Chem; 2023 Dec; 141():106906. PubMed ID: 37837728
[TBL] [Abstract][Full Text] [Related]
44. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
Lee BD; Dawson VL; Dawson TM
Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
[TBL] [Abstract][Full Text] [Related]
45. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
46. P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.
Kalogeropulou AF; Zhao J; Bolliger MF; Memou A; Narasimha S; Molitor TP; Wilson WH; Rideout HJ; Nichols RJ
Biochem J; 2018 Apr; 475(7):1271-1293. PubMed ID: 29519959
[TBL] [Abstract][Full Text] [Related]
47. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.
Nikonova EV; Xiong Y; Tanis KQ; Dawson VL; Vogel RL; Finney EM; Stone DJ; Reynolds IJ; Kern JT; Dawson TM
Hum Mol Genet; 2012 Jan; 21(1):163-74. PubMed ID: 21972245
[TBL] [Abstract][Full Text] [Related]
49. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
50. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Greggio E
Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
[TBL] [Abstract][Full Text] [Related]
51. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
52. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
Greggio E; Cookson MR
ASN Neuro; 2009 Apr; 1(1):. PubMed ID: 19570025
[TBL] [Abstract][Full Text] [Related]
53. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
Lee BD; Shin JH; VanKampen J; Petrucelli L; West AB; Ko HS; Lee YI; Maguire-Zeiss KA; Bowers WJ; Federoff HJ; Dawson VL; Dawson TM
Nat Med; 2010 Sep; 16(9):998-1000. PubMed ID: 20729864
[TBL] [Abstract][Full Text] [Related]
54. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.
Covy JP; Giasson BI
Biochem Biophys Res Commun; 2009 Jan; 378(3):473-7. PubMed ID: 19027715
[TBL] [Abstract][Full Text] [Related]
55. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation.
Kamikawaji S; Ito G; Sano T; Iwatsubo T
Biochemistry; 2013 Sep; 52(35):6052-62. PubMed ID: 23924436
[TBL] [Abstract][Full Text] [Related]
56. Modeling LRRK2 Pathobiology in Parkinson's Disease: From Yeast to Rodents.
Daniel G; Moore DJ
Curr Top Behav Neurosci; 2015; 22():331-68. PubMed ID: 24850078
[TBL] [Abstract][Full Text] [Related]
57. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
[TBL] [Abstract][Full Text] [Related]
58. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
[TBL] [Abstract][Full Text] [Related]
59. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
Tomiyama H; Li Y; Funayama M; Hasegawa K; Yoshino H; Kubo S; Sato K; Hattori T; Lu CS; Inzelberg R; Djaldetti R; Melamed E; Amouri R; Gouider-Khouja N; Hentati F; Hatano Y; Wang M; Imamichi Y; Mizoguchi K; Miyajima H; Obata F; Toda T; Farrer MJ; Mizuno Y; Hattori N
Mov Disord; 2006 Aug; 21(8):1102-8. PubMed ID: 16622854
[TBL] [Abstract][Full Text] [Related]
60. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
